Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity by Gamir-Morralla, A. et al.
OPEN
Development of a neuroprotective peptide that
preserves survival pathways by preventing Kidins220/
ARMS calpain processing induced by excitotoxicity
A Gamir-Morralla1,2,4, C López-Menéndez1,2,4, S Ayuso-Dolado1, GS Tejeda1, J Montaner3, A Rosell3, T Iglesias*,1,2,5 and
M Díaz-Guerra*,1,5
Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), has a central
role in the coordination of receptor crosstalk and the integration of signaling pathways essential for neuronal differentiation, survival
and function. This protein is a shared downstream effector for neurotrophin- and ephrin-receptors signaling that also interacts with the
N-methyl-D-aspartate type of glutamate receptors (NMDARs). Failures in neurotrophic support and glutamate signaling are involved in
pathologies related to excitotoxicity and/or neurodegeneration, where different components of these dynamic protein complexes result
altered by a combination of mechanisms. In the case of Kidins220/ARMS, overactivation of NMDARs in excitotoxicity and cerebral
ischemia triggers its downregulation, which contributes to neuronal death. This key role in neuronal life/death decisions encouraged us
to investigate Kidins220/ARMS as a novel therapeutic target for neuroprotection. As the main mechanism of Kidins220/ARMS
downregulation in excitotoxicity is proteolysis by calpain, we decided to develop cell-penetrating peptides (CPPs) that could result in
neuroprotection by interference of this processing. To this aim, we first analyzed in detail Kidins220/ARMS cleavage produced in vitro
and in vivo, identifying a major calpain processing site in its C-terminal region (between amino acids 1669 and 1670) within a sequence
motif highly conserved in vertebrates. Then, we designed a 25-amino acids CPP (Tat-K) containing a short Kidins220/ARMS sequence
enclosing the identified calpain site (amino acids 1668–1681) fused to the HIV-1 Tat protein basic domain, able to confer membrane
permeability to attached cargoes. Transduction of cortical neurons with Tat-K reduced Kidins220/ARMS calpain processing in a dose-
and time-dependent manner upon excitotoxic damage and allowed preservation of the activity of pERK1/2 and pCREB, signaling
molecules central to neuronal survival and functioning. Importantly, these effects were associated to a significant increase in neuronal
viability. This Kidins220/ARMS-derived peptide merits further research to develop novel neuroprotective therapies for excitotoxicity-
associated pathologies.
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Neurotransmitters and neurotrophins regulate nervous
system development, and preservation and remodeling of
adult neural circuits. Prominent roles are played by glutamate,
major excitatory neurotransmitter, and brain-derived neuro-
trophic factor (BDNF). By activating their receptors and
signaling pathways, these ligands regulate multiple neuronal
processes, including survival. Physiological stimulation of
N-methyl-D-aspartate type of glutamate receptors (NMDARs)
induces neuronal survival through extracellular signal-
regulated kinases (ERKs) activation,1 antioxidant defenses
induction,2 and cAMP response element-binding protein
(CREB) phosphorylation.3 In turn, CREB increases expression
of BDNF4,5 and its receptor tropomyosin-related kinase B
(TrkB).6,7 Neurotrophin receptors enhance neuronal survival
via signaling cascades involving PI3K-Akt, ERK,8,9 CREB10
and nuclear factor kappa-B (NF-κB).11 Signaling requires
large complexes formed at postsynaptic membranes by
receptors and effectors. For instance, NMDAR association
with ephrin receptor (Eph)B is critical for synaptic function,12,13
while EphB activation by ephrin-B modulates NMDAR-
dependent calcium influx and receptor expression.14 Likewise,
TrkB interacts with ephrin-A7 and EphA.15,16 In addition, Fyn
tyrosine-kinase associates to TrkB and NMDAR-GluN2B,17,18
while neural Shc (N-Shc), a neurotrophin signaling adaptor,
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also regulates NMDAR function.19 Coordination of these
receptors crosstalk requires their shared effector Kinase
D-interacting substrate of 220 kDa (Kidins220),20 also known
as ankyrin repeat-rich membrane spanning (ARMS).21
Kidins220 bears twelve ankyrin repeats, four trans-
membrane (TM) segments forming a KAP-NTPase
domain,20,22 a proline-rich region, a sterile alpha domain
(SAM) and a PDZ ligand (PDZ-L) at the C-terminus.20,21 It
interacts with Trk receptors21 and is obligatory for
neurotrophin-sustained ERK activation and neuronal
differentiation.23–25 In addition, Kidins220 associates with
NMDARs and modulates their ERK signaling and neuronal
survival.26
Excitotoxicity is a specific neuronal-death process due
to NMDAR overstimulation that contributes to neuro-
degeneration in acute disorders (ischemia, trauma and
epilepsy) or chronic neurodegenerative diseases (Alzheimer’s,
Parkinson’s or Huntington’s).27 Defective neurotrophic support
and signaling are also involved in neurodegeneration.28,29
Altogether, these conditions cause high mortality and/or
neurological impairment representing a social and health
challenge. As there are no satisfactory treatments, it is capital
to characterize excitotoxic mechanisms and how they affect
proteins fundamental to survival/death choices30 in order to
develop novel therapies. We discovered decreases in
NMDAR31,32 and TrkB33 signaling during excitotoxicity due to
activation of the Ca2+-dependent protease calpain and
transcriptional inhibition. Similar mechanisms control
Kidins220 downregulation that contributes to neuronal death
after NMDAR overactivation.26 Indeed, Kidins220 is crucial for
neuronal survival as its knockdown decreases ERK activation
and neuronal viability and enhances excitotoxic death.26 This
key role in neuronal life/death decisions points to Kidins220 as
a novel therapeutic target for neuroprotection. As calpain
processing is the major mechanism of Kidins220 down-
regulation in excitotoxicity, we approach here the design of a
neuroprotective peptide able to prevent Kidins220 calpain-
dependent loss. First, we analyzed Kidins220 processing and
identified a major calpain cleavage site within its C-terminus.
We then designed a cell-penetrating peptide (CPP) containing
the identified calpain site fused to a HIV-1 Tat protein basic
domain, which confers membrane permeability and capability
of crossing the blood–brain barrier (BBB).34,35 Transduction of
this peptide reduced Kidins220 calpain processing upon
excitotoxicity and significantly increased neuronal viability.
Results
Kidins220 C-terminus is a major calpain target in
excitotoxicity induced in vitro and in vivo. To develop a
neuroprotective strategy based on prevention of Kidins220
calpain processing induced by excitotoxicity, we first
characterized cleavage topology and kinetics. We treated
mature cortical neurons of 14 days in vitro (DIVs) with high
concentrations of NMDAR co-agonists, NMDA and glycine,
and analyzed Kidins220 by immunoblot using antibodies
recognizing a C-terminal peptide (Kid-Ct)20 or the N-terminal
region (Kid-Nt)36 (Figure 1a). As described,26 Kid-Ct showed
a rapid decrease of full-length (FL) Kidins220 but no
fragments, suggesting that those were very small and/or
unstable. However, Kid-Nt exposed a slower FL-Kidins220
decay, suggesting a prominent calpain target close to the
C-terminus (site 0, Figure 1b). Early cleavage at this
sequence likely produced a relatively stable N-terminal
fragment (Nt-0) difficult to resolve from FL-Kidins220
(Figure 1a). Thereafter, progressively smaller N-terminal
fragments (Nt-1/Nt-9) emerged, allowing prediction of nine
additional calpain targets within the KAP-NTPase domain
and likely interdomain sequences (Figure 1b). Absence of
complementary C-terminal fragments supported again the
presence of a highly efficient calpain site nearby Kidins220
C-terminus that, once processed, avoided detection with Kid-
Ct. Breakdown products (BDPs) from the widely used
calpain-substrate spectrin confirmed calpain activation, while
other neuronal proteins such as neuronal-specific enolase
(NSE) were not significantly modified (Figure 1a). Require-
ment of calpain activation for Nt-1/Nt-9 production was
corroborated by pre-incubation with calpain-specific inhibitor
III (CiIII) (Figure 1c), which strongly prevented NMDA-induced
processing in contrast to proteasome inhibitor lactacystin
(Lact). Thus, an important mechanism of Kidins220 excito-
toxic downregulation in cultured neurons is calpain proces-
sing of sequences downstream ankyrin repeats, being
prominent a C-terminal target.
Next, it was important to analyze Kidins220 cleavage
induced by in vivo excitotoxicity. We used a mice model of
focal cerebral ischemia produced by distal occlusion of middle
cerebral artery (dMCAO) where NMDAR overactivation is the
major mechanism of neurodegeneration.27 MCA compression
for 1 h followed by 24 h reperfusion induced large infarcts in
cortical areas of this artery territory (Figure 2a).37 We
compared Kidins220 levels in the infarcted and corresponding
contralateral regions (average infarct volume 29.9± 4mm3;
n= 4 animals) observing an important decrease in
FL-Kidins220 (Figure 2b). Kidins220 N-terminal fragments in
ischemic tissue were similar to those of neurons subjected to
excitotoxicity (see Figure 1a). However, differently from
neurons, Kid-Ct identified a C-terminal fragment in infarcted
tissue with an apparent molecular weight of 15 kDa (Ct-0).
Relative levels of Ct-0 correlated with the degree of calpain
activation, established by production of spectrin BDPs or
Kidins220 N-terminal fragments (Figure 2b), confirming the
importance of Kidins220 sequences nearby the C-terminus for
in vivo calpain cleavage in ischemic brain. A similar Ct-0
fragment appeared in neuronal extracts after in vitro addition of
purified calpain I (Figure 2c). The decrease of FL-Kidins220
and the corresponding accumulation of Ct-0 in a dose- and
time-dependent manner resulted from calpain cleavage as
they were inhibited by CiIII. In vitro digestion with calpain II
produced similar results (Supplementary Figure 1). Finally, we
confirmed that Ct-0 derived from Kidins220 as levels of this
fragment decreased in parallel to those of FL after Kidins220
lentiviral silencing26 (Supplementary Figure 2). Altogether,
these results demonstrate the existence of a calpain site
nearby Kidins220 C-terminus that is efficiently processed
in vivo after protease activation and produces a 15-kDa
fragment of low stability.
To facilitate detection and isolation of Ct-0, we used a
heterologous excitotoxicity system for ectopic expression of
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Kidins220-GFP-Ct and hypothesized that this approach might
help fragment stabilization. HEK293T cells co-transfected
with Kidins220-GFP-Ct andGluN1/GluN2A cDNAs, producing
functional NMDARs, were stimulated with NMDA (Figure 2d).
Anti-GFP antibodies showed limited FL-Kidins220-GFP-Ct
(FL-GFP) downregulation. However, an abundant short
fragment (Ct-0-GFP) was specifically induced from early
times upon NMDA treatment of GluN1/GluN2A-transfected
cells but absent in cells expressing an incomplete NMDAR.
The molecular weight of Ct-0-GFP (37 kDa) was compatible
with a fusion of GFP (26.9 kDa) and a 10-kDa Ct-0 fragment.
The discrepancy between Ct-0 deduced size or that found in
ischemic brain and neuronal extracts digested in vitro could be
due to post-translational modifications absent in HEK293 cells
or simply an effect of GFP fusion over Ct-0 electrophoretic
properties. Subunit-specific antibodies probed expression of
GluN1 and GluN2A and NMDA-dependent processing of
GluN2A, as expected.32 Thus, the modest excitotoxic
response observed in HEK293 cells versus neurons might
contribute together with GFP fusion to stabilize Kidins220
C-terminal fragments.
Identification of an evolutionary conserved sequence
motif for calpain cleavage within Kidins220 sequence. To
design a neuroprotective strategy to interfere Kidins220
excitotoxic processing, it was crucial to identify the major
C-terminal sequence early cleaved by calpain. Accurate
in silico prediction of Kidins220 calpain sites is difficult as
structural bases for calpain-substrate recognition are not well
defined38 and no consensus sequences exist. Therefore, we
decided to affinity purify Kidins220 Ct-0 fragment and
sequence its N terminus by Edman degradation to identify
Figure 1 Approximate mapping of Kidins220 processing sites recognized by calpain after induction of excitotoxicity. (a) Immunoblot analysis of primary neuronal cultures (DIV
14) treated with high concentrations of NMDA (100 μM) and glycine (10 μM), herein indicated as NMDA, for 0–6 h. Kidins220 antibodies recognizing a C-terminal peptide (amino
acids 1746–1762; Kid-Ct) or the N-terminal region (amino acids 1–402; Kid-Nt), or that specific for the protein neuronal-specific enolase (NSE) were used. Bands corresponding
to endogenous full-length (FL) Kidins220 or its different processing N-terminal fragments (Nt-0/Nt-9) are indicated. Calpain activation was established by analyzing processing of
FL spectrin (240 kDa) to characteristic breakdown products (BDPs; 145 and 150 kDa). (b) Schematic representation of Kidins220 protein domains with putative calpain targets.
From the N-terminal (Nt) to the C-terminal (Ct), we observe twelve ankyrin repeats, a KAP-NTPase domain including four transmembrane sequences (TM1–TM4; black boxes), a
proline-rich region (Pro), a sterile alpha motif (SAM) and a PDZ ligand (PDZ-L). The sequences recognized by Kidins220 antibodies are indicated by red (Kid-Nt) or green (Kid-Ct)
boxes. Approximate location of at least nine calpain targets (asterisk), inferred from Kid-Nt immunoblot, with estimated molecular weight of corresponding fragments (labeled Nt-1/
Nt-9) is indicated by horizontal arrows. The C-terminal Kidins220 region where a major calpain target is predicted (site 0) is indicated by a question mark. (c) Immunoblot analysis
showing the effect of inhibitors specific for calpain (calpain inhibitor III, CiIII, 20 μM) or the proteasome (lactacystin, Lact, 15 μM) on Kidins220 calpain processing induced in
excitotoxicity. Neuronal cultures were incubated with protease inhibitors for 1 h before addition of NMDAR co-agonists as above. Inhibitors were present for the duration of NMDA
treatment (4 h). Spectrin analysis demonstrates the efficiency of calpain inhibition
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this cleavage site. Because in vitro calpain processing
(Figure 2c) or GFP fusion (Figure 2d) apparently increased
fragment stability, we incubated extracts from HEK293T cells
expressing Kidins220-GFP-Ct with calpain I (Figure 3a).
Immunoblotting revealed FL-Kidins220-GFP dose- and
time-dependent processing and consequent Ct-0-GFP accu-
mulation. We also detected minor processing intermediates
(Ct-1-GFP/Ct-5-GFP, Figure 3b) that might be complemen-
tary to some N-terminal fragments (Figure 1) and stabilized
by GFP fusion. Furthermore, while Kid-Ct showed similar
efficiencies of calpain processing for endogenous or
Kidins220-GFP-Ct, higher levels of GFP-Ct-fused polypep-
tides accumulated compared with endogenous fragments
(Supplementary Figure 3). Next, we isolated Ct-0-GFP by
in vitro calpain digestion of lysates from Kidins220-GFP-Ct-
transfected HEK293T cells and GFP immunoprecipitation
(Supplementary Figure 4). We confirmed the efficiency of
Ct-0-GFP immunoprecipitation, the major protein within GFP
immunocomplexes (Figure 3c). Edman sequencing of pur-
ified Ct-0-GFP (Supplementary Figure 4) identified sequence
RTPSTV, which corresponded to rat Kidins220 amino acids
1670–1675 (Figures 3c and d). This result identified calpain
cleavage between amino acids 1669 and 1670 to produce a
C-terminal fragment of predicted molecular weight 10.2 kDa.
This cleavage site was completely conserved in human,
mice, chicken, frog and zebrafish (Figure 3d). Furthermore,
surrounding sequences were also highly conserved, support-
ing the importance of this calpain target for Kidins220
downregulation in excitotoxicity.
A CPP containing amino acids 1668–1681 inhibits
Kidins220 calpain-dependent downregulation. Next, we
designed a 27-amino acids CPP containing residues
47–57 of HIV-1 Tat protein fused to Kidins220 amino acids
1668–1681 (Figure 4a, Tat-K) to interfere Kidins220 calpain
recognition and excitotoxic processing. We also synthesized
a control-scrambled peptide where Kidins220 amino acids
were randomly organized (Figure 4a, Tat-S). First, we
assayed Tat-K efficacy to prevent Kidins220 in vitro calpain
processing (Figure 4b). Neuronal extracts incubated with
Figure 2 Kidins220 sequences approximately 15 kDa from the C-terminus are major calpain targets after calpain activation in vivo and in vitro. (a) Brain coronal sections of
mice subjected to transient cerebral ischemia induced by dMCAO incubated with vital stain TTC showing a cortical infarct in the MCA territory of the ipsilateral hemisphere. MCA
was compressed for 1 h followed by blood reperfusion for 24 h. (b) Analysis of Kidins220 processing after in vivo excitotoxicity induced by transient cerebral ischemia. Protein
extracts were prepared from cortical infarcted regions (I) and corresponding areas of the contralateral hemisphere (C) of four mice subjected to dMCAO (1–4). Immnuoblot
analysis of Kidins220 processing established a correlation between the degree of calpain activation, demonstrated by spectrin cleavage, the decrease of FL Kidins220, and the
accumulation of different N-terminal intermediates (Nt-s) and a 15-kDa C-terminal fragment (Ct-0). The presence of this Ct-0 fragment, observed in longer exposures of Kid-Ct
immunoblots, was higher in animals presenting a better calpain activation. (c) Protein extracts from cortical neurons subjected to in vitro digestion with purified calpain I (0, 20, 50
or 80 U/ml) for 15 or 30 min in the absence or presence of calpain inhibitor CiIII (20 μM). The decrease of FL Kidins220 due to calpain activity correlated with the generation and
accumulation of a major 15 kDa C-terminal fragment (Ct-0). (d) Analysis of Kidins220 C-terminal fragments produced in a heterologous system of excitotoxicity. To facilitate
detection of C-terminal fragments, Kidins220 rat-coding sequence fused to GFP at its C-terminus (Kidins220-GFP-Ct) was expressed in HEK293T cells together with HA-tagged
GluN1 and GluN2A, to produce a functional NMDAR, or GluN1 only, yielding an incomplete NMDAR. In HAGluN1/HAGluN2A-transfected cells stimulated with NMDA (0–6 h),
GFP antibodies mainly detected FL Kidins220-GFP-Ct (FL-GFP) and its fragment Ct-0-GFP. In parallel, and in contrast to GluN1, subunit GluN2A (FL) was also processed and
produced BDPs as expected for a calpain substrate. Neuronal-specific enolase (NSE) or β-actin levels were used as protein-loading controls
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calpain I and Tat-K showed less Ct-0 and increased FL-
Kidins220 resistance to processing compared with those
containing Tat-S. Thus, Tat-K could prevent Kidins220 in vitro
calpain degradation. Then, we confirmed peptide membrane
permeability and established optimal entry conditions. FITC-
labeled Tat-S (FITC-Tat-S) entered neurons in a dose-
dependent manner, the best results obtained for 10–25 μM
(Figure 4c). Intensity of internalized fluorescence was similar
at the different incubation times, suggesting relative peptide
stability once inside cells. Appropriate conditions for peptide
pre-incubation before induction of excitotoxicity were also set
by studying early kinetics of peptide delivery, observing
the highest fluorescence levels after 1 h (Supplementary
Figure 5). Finally, we analyzed Tat-K ability to reduce
Kidins220 calpain processing induced by NMDAR over-
activation. Neurons were pre-incubated for 1 h with Tat-K or
Tat-S (10 or 25 μM) before NMDA addition (Figure 4d).
A strong decrease in Kidins220 levels was concomitant to
calpain activation in Tat-S-treated neurons while that protein
was better preserved by Tat-K, with no apparent effect on
spectrin. To further characterize Tat-K actions, neurons were
pre-incubated with Tat-S or Tat-K (25 μM) and NMDA treated
for different times (Figure 4e). In the presence of Tat-S,
NMDA induced a strong decrease in Kidins220 from early
times (2 h) of excitotoxicity, an effect increased later on. In
contrast, pre-treatment with Tat-K significantly reduced
Kidins220 downregulation at 2 or 4 h of NMDA stimulation
(Figure 4e). Quantitation showed that Kidins220 levels
remained significantly higher after 4 h of NMDA incubation
in Tat-K (78±7%) compared with Tat-S-treated neurons
(53± 6%; Po0.001; n= 6; Figure 4f). This response was not
due to changes in Kidins220 basal levels induced by peptide
pre-incubation as they did not occur in non-excitotoxic
conditions (Supplementary Figure 6). We also analyzed
Tat-K effects on excitotoxic cleavage of other calpain
substrates that associate to Kidins220 and are important for
NMDAR signaling (Supplementary Figure 7). Pre-incubation
with Tat-K marginally preserved NMDA-induced processing
of components of the NMDAR complex such as GluN2A and
GluN2B26 subunits or their interacting protein PSD95, while
had no effect on spectrin. These interferences might also
have important consequences for neuroprotection as all
these proteins are central to neuronal survival and
functioning. In conclusion, these results demonstrate that
Tat-K, a CPP containing a major Kidins220 calpain-cleavage
site, is able to efficiently hinder processing of this protein at
early times of excitotoxicity.
Figure 3 Establishment of the major calpain-recognition sequence in Kidins220 C-terminus. (a) Immunoblot analysis of protein extracts obtained from HEK293T cells
expressing Kidins220-GFP-Ct subjected to in vitro digestion with purified calpain I (20 or 80 U/ml) for 15 or 30 min. The GFP antibody reveals processing of FL Kidins220-GFP-Ct
(FL-GFP) and the corresponding accumulation of a major C-terminal GFP-fused fragment (Ct-0-GFP) together with low amounts of additional fragments (Ct-1-GFP/Ct-5-GFP).
Spectrin processing and levels of β-actin were used as controls of calpain activity and protein loading, respectively. (b) Schematic representation of fusion protein Kidins220-GFP-
Ct with putative minor (Ct-1-GFP/Ct-5-GFP) and major (Ct-0-GFP) calpain targets (asterisks), their approximate location being inferred from immunoblots with antibodies specific
for GFP. The fragments produced, together with their estimated molecular weights, are indicated by horizontal arrows. The contribution of GFP to the molecular weight of those
fragments is depicted separately (green box). (c) Purification of Ct-0-GFP and Edman sequencing. Total lysates (TL) from HEK293T cells transfected with Kidins220-GFP-Ct
were left undigested or subjected to a preparative digestion with purified calpain (80 U/ml). Digested lysates were then immunoprecipitated (IP) with GFP antibodies. Small
fractions of total lysates or immunoprecipitates were analyzed with GFP antibodies to corroborate the accumulation and concentration of Ct-0-GFP fragment (highlighted by a red
box). The band corresponding to this fragment was cut from a preparative filter stained with Coomasie Blue and subjected to Edman degradation. The N-terminal sequence
obtained and the amino acids position (1670–1675) in rat protein (NP_446247) are shown below. (d) Comparison of rat Kidins220 region containing the major calpain cleavage
site identified above to homologous regions in five additional vertebrate species, human (NP_065789), mice (NP_001074847), chicken (XP_419939), frog (NP_001120159) and
zebrafish (AAH61450). A high level of sequence conservation is observed in all vertebrate species analyzed and, particularly, a seven amino acids stretch comprising Kidins220
calpain-processing site 0 (blue) is completely conserved
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Tat-K transduction confers neuroprotection and pre-
serves ERK1/2 and CREB survival pathways. We next
explored if inhibition of Kidins220 calpain processing by Tat-K
could neuroprotect from excitotoxicity and, in that case,
establish the protective mechanism. Excitotoxicity was
induced in neurons pre-incubated with CPPs followed by
fluorescence staining of viable and dead cells with calcein-
AM and propidium iodide (PI), respectively (Figures 5a and b).
In neurons pre-incubated with Tat-S, NMDA treatment
provoked a strong decrease in viability and a correlative
increase in death compared with untreated cultures
(Figure 5a). However, the number of viable neurons in Tat-
K-transduced NMDA-treated cultures almost doubled that
obtained in Tat-S-incubated cells (40± 7% versus 23±7%,
respectively, Po0.01; n=7; Figure 5b). Accordingly, the
percentage of dead neurons was also statistically different
(60±7% versus 77± 7%, Po0.01). The neuroprotective
effect of Tat-K after NMDAR overstimulation was also
analyzed by MTTassays (Figure 5c). The viability of neurons
incubated with NMDA for 6 h in the presence of Tat-S was
Figure 4 Design of a CPP able to specifically inhibit Kidins220 calpain processing induced by excitotoxicity. (a) Cell-membrane peptide Tat-K contains from the N- to the
C-terminus amino acids 47–57 of the HIV-1 Tat protein (italic) followed by two proline linker residues and rat Kidins220 amino acids 1668–1681 (bold), which include the major
calpain cleavage site (arrow). Control peptide Tat-S is similar to Tat-K but Kidins220 amino acids (bold) are randomly organized. (b) Analysis of Tat-K interference of in vitro calpain
processing of Kidins220. Protein extracts from cortical neurons were subjected to in vitro digestion with purified calpain I (20 U/ml) for 15 min in the presence of peptides Tat-K (K)
or Tat-S (S) (0.5 μM). Results were analyzed by immunoblot with Kidins220 (Kid-Ct), spectrin and NSE antibodies. (c) Establishment of optimum conditions for peptide entry into
cortical neurons. Primary cultures of neurons (DIV 14) were incubated with 5, 10 or 25 μM of FITC-labeled control peptide (FITC-Tat-S) for 2, 4 or 6 h and pictures were taken in a
conventional fluorescence microscope. Scale bar, 25 μm. (d) Dose response of Tat-K-specific interference of Kidins220 calpain processing induced by NMDAR overactivation.
Cortical neurons were pre-incubated for 1 h with 10 or 25 μM of Tat-K (K) or Tat-S (S) before NMDA addition for 4 h and analyzed by immunoblot with Kidins220 (Kid-Ct), spectrin
and NSE antibodies. (e) Time course of Tat-K-specific interference of Kidins220 calpain processing induced by excitotoxicity. Neurons were pre-incubated for 1 h with 25 μM of
Tat-K (K) or Tat-S (S) before NMDA addition for 2, 4 or 6 h and analyzed as before. (f) Quantitation of Tat-K protection of Kidins220 processing induced by excitotoxicity. Levels of
Kidins220 were established by densitometric analysis of immunoblots using NIH Image software and normalized to those of NSE present in the same samples. For each time
point, Kidins220 levels in neurons treated with NMDA in the presence of Tat-S or Tat-K are represented as relative values to those obtained in cultures incubated with the same
peptide but no NMDA, arbitrarily given a 100% value. Average of five independent experiments with S.E.M. is given. Statistical significance was determined by paired Student’s
t-test (**Po0.01, ***Po0.001)
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only 17±4% relative to non-stimulated cells while survival
increased to 41± 6% (Po0.05; n=5) in Tat-K-treated
neurons. These peptides had no toxicity as no significant
differences in viability were found in transduced versus non-
transduced neurons (Supplementary Figure 8). Our results
prove a clear neuroprotective effect of Tat-K on excitotoxicity
that correlates with this peptide ability to interfere Kidins220
calpain processing.
Maintenance of higher Kidins220 levels during excitotoxicity
by Tat-K treatment might allow preservation of important
neuronal survival pathways where this protein participates. In
neurons, Kidins220 silencing decreases basal ERK1/2 activity,
alters ERK1/2 activation induced by NMDAR overstimulation
and reduces neuronal survival.26 Therefore, calpain-induced
Kidins220 downregulation might significantly contribute to
excitotoxic neuronal death affecting this pathway. We
analyzed ERK1/2 activation in cultures pre-incubated with
Tat-K or Tat-S and treated with NMDA for 2 h, time of maximum
kinase activation,26 or 4 h (Figures 6a and b). As in control
neurons, NMDA induced a transient pERK1/2 augmentation in
Tat-S and Tat-K pre-treated cultures (Figures 6a and b).
However, ERK1/2 activation was enhanced by Tat-K and
correlated with inhibition of Kidins220 processing. Compared
with control neurons, 2 h of NMDA stimulation augmented
pERK1 by a factor of 8±1 in Tat-K-treated cultures, value
significantly higher than that obtained with Tat-S (3± 1,
Po0.01; n=5) (Figure 6b). NMDAR overactivation also
induces a dominant CREB shut-off that affects neuronal
Figure 5 Neuroprotective effect exerted by Tat-K transduction on excitotoxic neuronal death. (a) Effect of Tat-K on cell death induced by NMDAR overactivation. Primary
cultures of cortical neurons (DIV 14) were pre-incubated for 1 h with Tat-S or Tat-K (25 μM) and treated with NMDA for 4 h or left untreated. Next, viable and dead cells were
visualized by simultaneous fluorescence staining with calcein-AM (1 μM; green) and propidium iodide (PI; 0.5 mM; red), respectively, for 15 min at 37 º C in the dark.
Representative images for each condition are shown. Scale bar, 25 μm. (b) Quantitation of Tat-K effect on the relative percentage of viable/dead neurons found in excitotoxic
conditions. A minimum of five random fields containing at least 500 neurons each were counted per experimental condition. The percentage of viable (green bars) versus death
(red bars) neurons was expressed relative to the total number of neurons examined, arbitrarily given a 100% value. Average of seven independent experiments with S.E.M. is
represented. Statistical significance was determined by paired Student’s t-test (**Po0.01). (c) Quantitation of the effect of Tat-K on neuronal viability after induction of
excitotoxicity. Cultures of cortical neurons were pre-incubated for 1 h with Tat-S or Tat-K (25 μM) and treated with NMDA for 4 or 6 h as before or left untreated. Neuronal viability
was established by MTTreduction assay after subtracting the contribution of the glial cells present in the mixed cultures to absorbance as indicated in the Methods section. For
each time point, viability of neurons treated with NMDA in the presence of Tat-S or Tat-K is represented relative to that of neurons incubated with the same peptide but no NMDA,
arbitrarily given a 100% value. Average of five independent experiments with S.E.M. is given. Statistical significance was determined by paired Student’s t-test (*Po0.05,
**Po0.01)
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survival.3 Thus, we also analyzed CREB activity in these
experimental conditions and found that Tat-K treatment before
excitotoxicity also rendered significant increases in active pCREB
(Figures 6a and c). Importantly, PI3K/Akt survival pathway, which
is also deactivated by excitotoxicity,39 was unaffected by Tat-K
as determined detecting active pAkt (Figure 6a).
In conclusion, our results unveil a novel strategy for
neuroprotection based on the use of Tat-K, and strongly
support that this peptide, by hindering Kidins220 calpain
processing induced by excitotoxicity, is able to decrease
neuronal death and specifically enhance ERK1/2 and CREB
activity, preserving signaling pathways central to neuronal
survival.
Discussion
Herein we have discovered a major Kidins220 calpain
cleavage site highly conserved in vertebrates. On the basis
of this sequence, we have developed a neuroprotective
peptide that decreases Kidins220 calpain processing and
excitotoxic death in cortical neurons, establishing this
sequence motif as a novel target for neuroprotection in
excitotoxicity-associated pathologies. Analysis of Kidins220
cleavage in excitotoxic neurons using a N-terminal antibody
(Kid-Nt) allowed prediction of at least nine calpain targets
downstream ankyrin repeats. Progressive accumulation of
shorter intermediates along NMDA treatment suggested a
similar processing efficiency for all of them. However, an
antibody recognizing Kidins220 last 17 amino acids (Kid-Ct)
could not detect fragments in excitotoxic neurons suggesting a
nearby and prominent calpain-cleavage site, and the produc-
tion of a low-stability fragment. Supporting this hypothesis,
brain tissue from ischemic mice rendered a 15-kDa C-terminal
Kidins220 fragment, which could be also observed by in vitro
digestion of neuronal lysates with calpain I or II. The lower
stability of this fragment in the cellular model of excitotoxicity
might be simply related to a higher activity, comparedwith cells
in vivo, of additional proteases further degrading the 15-kDa
fragment. Anyway, appearance of this fragment in ischemic
brain supported the relevance of pursuing the identification of
that specific calpain-cleavage site within Kidins220 to develop
a neuroprotective strategy.
The pre-eminence of this calpain site at the very C-terminal
region indicates that Kidins220 PDZ-L will be rapidly lost in
Figure 6 ERK1/2 and CREB survival pathways are preserved in excitotoxic conditions in neurons treated with Tat-K. (a) Effect of Tat-K on ERK1/2, AKTand CREB activation
induced by NMDAR overactivation. Neurons were pre-incubated for 1 h with 25 μM of Tat-K (K) or Tat-S (S) before NMDA addition for 2 or 4 h and analyzed by immunoblot with
phospho-specific antibodies recognizing the active forms of ERK1/2 (pERK1/2, Thr202/Tyr204), AKT (pAKT, Ser473) and CREB (pCREB, Ser133). (b) Quantitation of Tat-K effect on
pERK1/2 levels. Levels of pERK1 and pERK2 were established by densitometric analysis of immunoblots using NIH Image software and normalized to those of NSE present in
the same samples. For each time point, pERK1 or pERK2 levels in neurons treated with NMDA in the presence of Tat-S or Tat-K were represented as fold increase compared with
those obtained in cultures incubated with the same peptide but no NMDA, arbitrarily given a value of one. Average of five independent experiments with S.E.M. is given. Statistical
significance was determined by paired Student’s t-test (*Po0.05, **Po0.01). (c) Quantitation of Tat-K effect on CREB activation. Levels of pCREB were established and
normalized as before, and represented as percentage of those obtained in cultures incubated with the same peptide but no NMDA, arbitrarily given a 100% value. Average of three
independent experiments with S.E.M. is given. Statistical significance was determined by paired Student’s t-test (*Po0.05, **Po0.01)
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excitotoxicity having important functional consequences. This
PDZ-L is responsible for Kidins220 localization at the
neuromuscular junction through association with α-syntrophin,
a PDZ protein enhancing EphA4 signaling in a Kidins220-
dependent manner40 and known to associate with NMDAR-
GluN2A-C subunits.41 In addition, Kidins220 PDZ-L interacts
with the PDZ protein S-SCAM forming a tetrameric complex
with PDZ-GEF1 and Trk,25 a major component for
neurotrophin-induced sustained ERK stimulation leading to
differentiation. Therefore, Kidins220 PDZ-L cleavage will
rapidly uncouple this effector from these and other yet
unknown downstream signaling pathways and hamper func-
tions mediated by this motif. Some minor Kidins220 calpain
sites might be located at KAP-NTPase domain bearing the
four TM segments.20 Other NTPases in this KAP family have
been suggested to participate in assembling/disassembling of
signaling complexes mostly associated to the cytosolic side of
cell membranes in aNTPase-dependent way.22 Independently
of Kidins220 participation in similar functions, processing
of KAP-NTPase domain would primarily affect Kidins220
putative intrinsic enzymatic activity. In addition, as TM4
mediates Kidins220/Trk interaction,23 calpain cleavage
at this domain might impact its role as neurotrophin effector.
The remaining processing sites could occur in Kidins220
interdomain sequences, a frequent trend among calpain
substrates.42
Because in vitro excitotoxicity produced a highly unstable
Kidins220 C-terminal fragment, we obtained a more stable
GFP-fused fragment by in vitro calpain processing of
Kidins220-GFP-Ct. By purifying this fragment, we identified
the precise calpain cleavage site between amino acids 1669
and 1670 within rat Kidins220 sequence. Mechanisms of
calpain substrate recognition and cleavage are largely
unknown38 and there is no consensus recognition sequence.
Different bioinformatic tools allow in silico predictions based
on empirically derived rules for position-based residues
preference (Position-Specific Scoring Matrix Methods, PSSM),
Support Vector Machine (SVM) algorithms for machine
learning (Linear or Radial Basis Function Kernel, Multiple
Kernel Learning),43 or a Group-Based Prediction System
(GPS) algorithm.44 We analyzed Kidins220 C-terminal 1000
amino acids using these tools (available at http://www.calpain.
org and http://ccd.biocuckoo.org) and found a coincident hit
between amino acids 1669–1670, the site identified by Edman
sequencing. The resulting 93-amino-acids polypeptide bears
a destabilizing N-terminal arginine that might be a target for
the Arg/N-end rule pathway and explain its short life.45
Interestingly, seven amino acids contained within this proces-
sing site are completely conserved in six different vertebrate
species, including humans, supporting the importance of this
sequence for Kidins220 downregulation in excitotoxicity.
Calpain activation regulates neuronal death in brain
damage and neurodegeneration46,47 and, therefore, pharma-
cological inhibitors have been considered as potential
neuroprotective drugs.48,49 However, as this protease is
likewise required for normal neuronal function, calpain
inhibition promotes neuronal survival after injury but also
causes deficits in spine density and dendritic branching
complexity associated with impaired LTP and spatial
memory.50 The use of peptides to interfere calpain pathological
activities on specific substrates is emerging as an alternative
to generic inhibitors. It has already succeeded in blocking
NMDA-induced truncation of mGluR1α51 or transient-receptor
potential canonical 6 (TRPC6) channel,52 proteins having
neuroprotective roles. We have designed a peptide that
inhibits Kidins220 excitotoxic calpain downregulation and
tested if stabilization of this protein, central to neuronal
physiology (reviewed in Neubrand et al.53), resulted in
neuroprotection. This peptide, Tat-K, bearing the identified
calpain-recognition sequence (amino acids 1668–1681),
efficiently inhibits early NMDA-induced Kidins220 processing
and exhibits neuroprotection against in vitro excitotoxicity. The
decrease of Tat-K efficacy after 4 h of NMDAR overactivation
is probably consequence of intrinsic peptide instability and/or
inactivation by calpain processing once inside neurons.
Anyway, these neuroprotective effects could be still sufficient
in vivo to rescue neurons of the ischemic penumbra from
secondary death induced by dying cells in the infarct core.
Tat-K-induced neuroprotection correlated with specific
preservation of ERK1/2 and CREB activities, both central to
neuronal survival. Excitotoxic regulation of ERK activity highly
depends on experimental conditions. In our model, where both
synaptic and extrasynaptic NMDARs are overstimulated and
downregulated, we demonstrated an early activation
of ERK peaking at 2 h,26 which is probably induced by the
synaptic pool of receptors, followed by a gradual shut-off
possibly derived from NMDAR downregulation.31,32 Kidins220
silencing hampers sustained neurotrophin-induced ERK1/2
activation,23,24 decreases basal andNMDA-dependent ERK1-
/2 activity and neuronal viability, and enhances excitotoxic
death.26 Thus, inhibition of Kidins220 processing by Tat-K
might help to preserve ERK1/2 signaling, which mediates
synaptic NMDAR-dependent neuronal plasticity and survival.1
In addition, CREB activity preservation in excitotoxicity by
Tat-K would be highly relevant to neuronal viability and
function because this transcription factor is involved in
activity-dependent3 or neurotrophin-mediated10 neuronal
plasticity and survival. A secondary mechanism induced by
Tat-K might also have a minor contribution to maintenance of
ERK1/2 and CREB activities. Unlike generic calpain inhibitors,
Tat-K did not have a general effect on excitotoxicity-induced
processing of alternative calpain substrates such as spectrin.
However, a small Tat-K effect was observed on stability of
other Kidins220-associated proteins undergoing calpain
cleavage during excitotoxicity such as NMDAR-GluN2-
subunits26 or PSD95. This fact supports the existance of an
indirect mechanism, probably derived from Kidins220 pre-
servation, responsible of partial stabilization of NMDAR
complexes. As these complexes are central to neuronal
survival and function, this secondary mechanism of Tat-K
action could be also important for neuroprotection.
CPP-based strategies similar to the one described here
have shown a great potential for the treatment of acute and
chronic disorders of the nervous system,54 mostly due to their
low toxicity and capability to cross cell membranes and
BBB.34,35 Results of a phase-2 trial in patients undergoing
endovascular aneurysm repair showed a decrease in the
number of ischemic lesions typically induced by surgery
after administration of Tat-NR2B9c.55 This CPP contains
NMDAR–GluN2B–PDZ-L and dissociates a ternary complex
Kidins neuroprotective peptide for excitotoxicity
A Gamir-Morralla et al
9
Cell Death and Disease
formed with PSD95 and nNOS, uncoupling NMDARs from
neurotoxic signaling56 and reducing neuronal damage in
ischemia models without affecting synaptic activity.56,57
Additional therapeutic strategies aimed to prevent down-
regulation of proteins that, like Kidins220, are important to
neuronal survival have a great potential for neuroprotection in
excitotoxicity-associated pathologies.
Materials and Methods
Materials and chemicals. NMDA, glycine, cytosine ß-D-arabinofuranoside
(AraC), poly-L-lysine, L-laminin and propidium iodide were acquired from Sigma Co.
(St. Louis, MO, USA). Calpain I (μ-calpain), calpain II (m-calpain), carbobenzoxy–
valinyl–phenylalaninal (CiIII) and lactacystin (Lact) were from Calbiochem–Merck
Bioscience (Darmstadt, Germany), and antagonist 2-amino-phosphopentanoic acid
(DL-AP5) from Tocris (Bristol, UK). Lipofectamine 2000, Glutamax and Calcein-AM
were purchased from Invitrogen-Live Technologies (Carlsbad, CA, USA). ECL
Western Lighting Chemiluminisence Reagent Plus was from Perkin-Elmer Life
Sciences (Boston, MA, USA) and BCA reagent was from Pierce Thermo Scientific
(Rockford, IL, USA). Tat-S, FITC-Tat-S and Tat-K peptides were obtained from
Immunostep (Salamanca, Spain).
Antibodies. Rabbit polyclonal antibodies recognizing N-terminal (Kid-Nt)36
(generously provided by Dr. G. Schiavo) or C-terminal (Kid-Ct)20 regions of
Kidins220 were previously described. Rabbit polyclonal antibodies against active
phospho-p44/p42 MAPK (Thr202/Tyr204), herein pERK1/2, and phospho-Akt kinase
(Ser473) were from Cell Signaling Technology (Beverly, MA, USA) while those for
active phospho-CREB (Ser133) and NSE were from Millipore Corporation (Billerica,
MA, USA) and ICN Biomedicals (Costa Mesa, CA, USA), respectively. Mouse
monoclonal antibodies against ß-actin, GluN2B and GluN1 were purchased from
Sigma Co., BD Biosciences (San Jose, CA, USA) and Pharmigen (San Diego, CA,
USA), respectively. Mouse monoclonal antibodies recognizing non-erythroid spectrin
and PSD95 were from Chemicon (Temacula, CA, USA). Mouse monoclonal and
rabbit polyclonal antibodies against GFP were obtained from Invitrogen-Live
Technologies. Goat and rabbit polyclonal antibodies recognizing, respectively,
GluN2A C-terminus and p44/p42 MAPK (herein total ERK1/2) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-
conjugated antibodies were from General Electric (Fairfield, CT, USA).
Animal model of transient cerebral ischemia. All animal procedures
were performed in compliance with Spanish legislation and European Union
directives and approved by the local Animal Care Committee (protocol number
48/13, Vall d’Hebron Research Institute). Adult male Balb/c mice (25–30 g; Charles
River Laboratories, Cerdanyola, Spain) were given free access to food and water
before surgery, performed as previously described.37 Mice were anesthesized with
isoflurane (4% for induction, 2% for maintenance in air, 79% N2 : 21% O2; Abbot
Laboratories, Madrid, Spain). Body temperature was maintained at 36.5–37 °C
using a self-regulating heating blanket and a rectal probe. An incision was made
between the left eye and ear under an operating microscope (Leica MS5; Leica,
Heerburg, Switzerland) and the temporal muscle divided, exposing the skull lateral
aspect. The MCA was identified through the semi-translucent skull, and a small burr
hole (2–3-mm diameter) was made with a microdrill at the level of the inferior
cerebral vein to expose the M1 portion, leaving the dura intact. Drying injury of the
tissue was prevented by continuous hydration via saline application to the area.
Regional cerebral blood flow (CBF) was recorded from 5 min before MCAO to 5 min
after reperfusion by laser Doppler flowmetry using a flexible fibreoptic (0.5-mm
diameter; Moor Instruments, Devon, UK) placed on the surface of the M1 parietal
branch bifurcation. The MCA was directly compressed using a micromanipulator
holding a 30G blunted needle (0.4-mm diameter). After 60 min of occlusion, the
needle was carefully removed and the blood flow restored. Arterial occlusion was
considered successful when CBF was maintained for 60 min below 20% of baseline
value, and reperfusion if CBF recovered to at least a 75% of baseline values.
Twenty-four hours after blood reperfusion, animals were killed and their brains
sectioned into 1-mm-thick coronal slices and briefly stained with a 2% solution of
triphenyltetrazolium chloride (TTC; Merck Bioscience, Darmstadt, Germany) in the
cold to avoid endogenous post-mortem calpain activation. The unstained area of the
cerebral cortex, defined as infarcted tissue, as well as the corresponding region in
the contralateral hemisphere were dissected to prepare protein lysates, frozen and
stored at − 80 °C until use.
Primary culture and treatment of cortical neurons. Neuronal cultures
were prepared from cerebral cortex of 19-day-old Wistar rat embryos as we have
previously described.26,31 Rats were obtained from the animal care facility at the
Instituto de Investigaciones Biomedicas “Alberto Sols” (CSIC-UAM, Madrid, Spain).
Animal procedures were approved by the CSIC ethical committee and performed in
compliance with European Directive 2010/63/EU. Neurons were used after 14 days
in vitro (DIVs) and pre-treated or treated for different times, as indicated, with the
following concentrations of reactives: 100 μM NMDA, 10 μM glycine, 20 μM CiIII,
15 μM lactacystin and 5, 10 or 25 μM Tat-S or Tat-K. Excitotoxicity was induced by
overstimulation of cortical neurons with NMDAR co-agonists NMDA and glycine
(herein denoted NMDA). Unless otherwise stated, inhibitors and Tat-peptides were
added 1 h before NMDA treatment and remained in the culture media for the
duration of the experiment. When indicated, FITC-conjugated Tat-S was used, and
its entrance into cultured neurons was followed by in vivo fluorescent microscopy
using an Eclipse TE2000-U Nikon microscope and a Hamamatsu digital camera
C10600. Pictures were processed with NIS-Elements BR 3.00, SP6 (Nikon
Laboratory Imaging, Prague, Czech Republic) and Adobe CS3 Extended software
(Adobe Systems Inc., San Jose, CA, USA).
cDNA constructs. Plasmid driving the expression of N-terminal tagged rat
HA-GluN2A subunit has been previously described32 and contains a hemagglutinin
(HA) epitope between residues 51 and 52 of this protein. To obtain plasmid Syn-HA-
GluN1, a BamHI fragment isolated from pME18S-HA-GluN1 (a generous gift from
Dr. T. Yamamoto, University of Tokyo, Tokyo, Japan17) was subcloned into the Syn-GFP
lentiviral plasmid32 digested as before. This plasmid produces a GluN1 subunit with an
HA epitope between amino acids 27 and 28. The vector Kidins220-GFP-Ct encoding
rat Kidins220 fused at the C-terminal with GFP has been previously used,58 and was
generated by subcloning a SmaI/NdeI fragment containing FL rat Kidins220 cDNA from
pGEMT easy (Promega Corporation, Madison, WI, USA) into pEGFP-N2 SmaI site.
Culture and transfection of HEK293T-cells. Human embryonic kidney
293T cells (HEK293T) were cultured at 37 °C in Dulbecco's modified Eagle's
medium (Invitrogen-Live Technologies), supplemented with 10% fetal bovine serum,
2 mM glutamine and 100 U/ml of penicillin/streptomycin in an humidified
atmosphere containing 5% CO2. Transfection was performed in serum-free medium
with Lipofectamine 2000 reagent and, 4 h after addition, liposomes were removed
and cells fed with supplemented medium and maintained in culture for 48 h. In those
experiments where HA-GluN1 and HA-GluN2A subunits were co-expressed with
Kidins220-GFP-Ct, the NMDAR competitive antagonist DL-AP5 (2 mM) was added
after transfection to prevent HEK293Texcitotoxic death by NMDAR activation due to
glutamate present in the culture medium.59 Removal of the antagonist was
performed just before NMDA stimulation.
Lentiviral infection of neuronal cultures. Plasmids and lentivirus
suspensions were prepared as previously described.26 Neurons grown for eight
DIVs were transduced with lentivirus expressing Kidins220 shRNA (shK) or a
control shRNA (shC) directly added to the growing media and infection proceeded
for six additional days.
Preparation of protein extracts and immunoblot analysis. Protein
extracts from primary cultures, HEK293T or brain tissue were prepared as
described.26 Equal amounts of total lysates were resolved in SDS-PAGE and
analyzed by immunoblot. Membranes were incubated with different primary and
secondary antibodies and immunoreactive bands were detected by ECL.
Calpain I in vitro proteolysis and prediction of calpain putative
cleavage sites. Cell extracts were digested in vitro with purified calpain I or
calpain II as reported.26 When indicated, 20 μM CiIII or 0.5 μM Tat-peptides were
added to lysates immediately before protease addition. Calpain activation was
established by immunoblot analysis through the detection of full length brain spectrin
(FL) and its BDPs. Analysis of the potential calpain cleavage sites in rat Kidins220 last
C-terminal 1000 amino acids was performed using the online services provided by
Calpain Modulatory Proteolysis Database (CaMPDB; http://www.calpain.org) and
GPS-Calpain Cleavage Detector (GPS-CCD; http://ccd.biocuckoo.org). Predictions
from five different algorithms (Linear or Radial Basis Function Kernel, PSSM, MKL
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and GPS 2.0) were run. The results were compared for the identification of common
putative cleavage sites present in Kidins220 C-terminus.
Edman N-terminal sequencing of calpain cleavage sites. Total
lysates from HEK293T cells expressing Kidins220-GFP-Ct fusion protein were
digested with 80 U/ml of purified calpain I, as above. The C-terminal fragments
generated after in vitro proteolysis were immunoprecipitated using a rabbit
polyclonal anti-GFP antibody, resolved on SDS-PAGE, transferred to PVDF
membranes and stained with Coomasie Blue R-250. The band of interest was cut,
washed twice and kept at 4 °C until Edman degradation analysis. Sample duplicates
were run in parallel and analyzed by immunoblot with the GFP antibody in order to
ensure that electrophoretic mobility of purified bands matched that previously
detected in HEK293T digestions. Edman N-terminal sequencing was performed by
the Proteomic Service of the Centro de Investigaciones Biológicas (CSIC, Madrid,
Spain). Six rounds of protein degradation followed by HLPC identification of excised
amino acids revealed the sequence of interest.
Assessment of neuronal viability in primary cultures. Measurement
of neuronal survival by MTT reduction assay (Sigma Co.) was performed as
previously described.26,31 As we are using primary cultures containing cortical
neurons and glial cells, we established the contribution of glia viability to total values
by exposing sister cultures to 400 μM NMDA, 10 μM glycine for 24 h, conditions
which induce nearly complete neuronal death and no glial damage. After subtracting
this absorbance value, we obtained the viability of the neuronal subpopulation. For
Calcein-AM/propidium iodide staining, neuronal cultures grown on Ibidi l-Slide 8-well
chambers (IBIDI LLC Martinsried, Germany) were left untreated or stimulated with
NMDA for 4 h. Then, culture media was replaced by serum-free Neurobasal medium
(Invitrogen-Live Technologies) containing a mixture of 1 μM Calcein-AM, a highly
permeable non-fluorescent molecule transformed to fluorescent calcein dye in
viable cells, and 0.5 mM propidium iodide which can only reach the nucleus of dead
cells. Incubation proceeded for 15 min at 37 °C and neuronal viability was assessed
by time-lapse microscopy using the Cell Observer Z1 (Carl Zeiss MicroImaging) at
37 °C and 5% CO2/95% air, AxioVision 4.8 imaging software and a Cascade 1 k
camera. A minimum of five random fields and at least 500 cells were counted for
each sample. Only cells with a clear neuronal morphology were considered for
further analysis. The percentage of viable (green) or death (red) neurons was
expressed relative to the total number (green+red) of cells examined per condition.
Quantitative and statistical analysis. Immunoblot signals were quantified
by densitometric analysis (NIH Image), normalized using NSE and expressed
relative to values obtained in their respective controls. Results are shown as
mean±S.E.M. of 3–7 independent experiments. Statistical significance was
determined by Student’s t-test. A P-value smaller than 0.05 was considered
statistically significant: *Po0.05, **Po0.01, *** Po0.001.
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